Log In
Print
BCIQ
Print
Print this Print this
 

actoxumab/bezlotoxumab (MDX-066/MDX-1388) (MK-3415A)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionCombination of two human mAbs targeting against Clostridium difficile toxins A and B
Molecular Target Clostridium.difficile toxin A (TcdA) ; Clostridium.difficile toxin B (TcdB)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationClostridium
Indication DetailsTreat Clostridium difficile infection (CDI)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today